Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Roche has agreed to a $5.3 billion deal with Zealand Pharma to develop the obesity drug candidate petrelintide, including a ...
Monday, September 8, 2025
Tag: Zealand Pharma A/S
Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
Shares of Novo Nordisk surged 10% following positive early-stage results for its once weekly amycretin obesity drug, which led to ...
News Summarized. Time Saved. Bite-sized news briefs for busy people. No fluff, just facts.